Dr. Corbin Bachmeier of the Roskamp Institute is currently investigating the drug efflux transport interactions of various antidepressants in collaboration with Dr. Gary Levin of the Lake Erie College of Osteopathic Medicine (LECOM) in Bradenton, FL. Dr. Bachmeier and Dr. Levin are co-investigators of a grant, provided by Wyeth Pharmaceuticals, which examines the interactions of two antidepressant medications currently on the market, venlafaxine (Effexor) and desvenlafaxine (Pristiq), with the drug efflux transport proteins P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Previous efforts by this group found that treatment with venlafaxine in caco-2 cells, a model of intestinal absorption, induced the mRNA expression levels for P-gp. This work is reported in the scientific journal Human Psychopharmacology: Clinical and Experimental (Ehret et al., 2007). Their existing research aims to expound upon these findings by not only examining the impact of treatment with venlafaxine and its metabolite, desvenlafaxine, on the expression of P-gp at the protein level, but also determine their effect on BCRP protein expression levels. In addition to testing in the caco-2 cells, this research will also evaluate the impact of these drugs on transporter expression in brain endothelial cells, which constitute the blood-brain barrier (BBB). This research will examine the potential for drug-drug interactions with these therapies and may influence the manner in which these drugs are currently prescribed.
The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949